HSA
NRIX icon

Hussman Strategic Advisors’s Nurix Therapeutics NRIX Stock Holding History

Hussman Strategic Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,000
Closed -$499K – 267
2025
Q1 		$499K Buy
+42,000
New +$702K 0.12% 197

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hussman Strategic Advisors's NRIX Position: Q2 2025 in Review

Hussman Strategic Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 42,000 shares — an estimated $499K sold.

Hussman Strategic Advisors first reported a position in NRIX in Q1 2025 and held it in 1 quarter. The position peaked at $499K in Q1 2025. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Hussman Strategic Advisors reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 42,000 Nurix Therapeutics shares in Q2 2025, an estimated $499K.
  • Hussman Strategic Advisors first reported a position in Nurix Therapeutics in Q1 2025 and held it in 1 quarter.
  • Hussman Strategic Advisors's Nurix Therapeutics position peaked at $499K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Hussman Strategic Advisors's 13F filing for Q2 2025, filed 5 Aug 2025.